• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Sierra Oncology Inc. (Amendment)

    2/14/22 4:21:16 PM ET
    $SRRA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SRRA alert in real time by email
    SC 13G/A 1 tm226174d16_sc13ga.htm SC 13G/A

     

     

     

      UNITED STATES  
      SECURITIES AND EXCHANGE COMMISSION  
      Washington, D.C. 20549  
         

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*

     

    Sierra Oncology, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

     

    82640U107

    (CUSIP Number)

     

    December 31, 2021

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨ Rule 13d-1(b)
       
    x Rule 13d-1(c)
       
    ¨ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 82640U107
     
      1. Name of Reporting Persons
    Venrock Healthcare Capital Partners II, L.P.
     
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) x(1)
        (b) o
     
      3. SEC Use Only
     
      4. Citizenship or Place of Organization
    Delaware
         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With:
    5. Sole Voting Power
    0
     
    6. Shared Voting Power
    984,746(2)
     
    7. Sole Dispositive Power
    0
     
    8. Shared Dispositive Power
    984,746(2)
     
      9. Aggregate Amount Beneficially Owned by Each Reporting Person
    984,746(2)
     
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) o
     
      11. Percent of Class Represented by Amount in Row (9)
    6.1%(3)
     
      12. Type of Reporting Person (See Instructions)
    PN
               

     

     

    (1)Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, VHCP Management II, LLC, VHCP Management III, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    (2)Consists of (i) 130,138 shares of common stock issuable upon exercise of Series A Warrants and 130,138 shares of common stock issuable upon exercise of Series B Warrants held by Venrock Healthcare Capital Partners II, L.P.; (ii) 52,721 shares of common stock issuable upon exercise of Series A Warrants and 52,721 shares of common stock issuable upon exercise of Series B Warrants held by VHCP Co-Investment Holdings II, LLC; (iii) 281,411 shares of common stock issuable upon exercise of Series A Warrants and 281,411 shares of common stock issuable upon exercise of Series B Warrants held by Venrock Healthcare Capital Partners III, L.P.; and (iv) 28,103 shares of common stock issuable upon exercise of Series A Warrants and 28,103 shares of common stock issuable upon exercise of Series B Warrants held by VHCP Co-Investment Holdings III, LLC.

     

    (3)This percentage is calculated based upon (i) 15,055,040 shares of common stock outstanding as of November 1, 2021, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 5, 2021, plus (ii) 984,746 shares of common stock issuable upon exercise of warrants held by the Reporting Persons.

     

     

     

     

    CUSIP No. 82640U107
     
      1. Name of Reporting Persons
    VHCP Co-Investment Holdings II, LLC
     
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) x(1)
        (b) o
     
      3. SEC Use Only
     
      4. Citizenship or Place of Organization
    Delaware
         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With:
    5. Sole Voting Power
    0
     
    6. Shared Voting Power
    984,746(2)
     
    7. Sole Dispositive Power
    0
     
    8. Shared Dispositive Power
    984,746(2)
     
      9. Aggregate Amount Beneficially Owned by Each Reporting Person
    984,746(2)
     
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) o
     
      11. Percent of Class Represented by Amount in Row (9)
    6.1%(3)
     
      12. Type of Reporting Person (See Instructions)
    OO
               

     

     

    (1)Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, VHCP Management II, LLC, VHCP Management III, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    (2)Consists of (i) 130,138 shares of common stock issuable upon exercise of Series A Warrants and 130,138 shares of common stock issuable upon exercise of Series B Warrants held by Venrock Healthcare Capital Partners II, L.P.; (ii) 52,721 shares of common stock issuable upon exercise of Series A Warrants and 52,721 shares of common stock issuable upon exercise of Series B Warrants held by VHCP Co-Investment Holdings II, LLC; (iii) 281,411 shares of common stock issuable upon exercise of Series A Warrants and 281,411 shares of common stock issuable upon exercise of Series B Warrants held by Venrock Healthcare Capital Partners III, L.P.; and (iv) 28,103 shares of common stock issuable upon exercise of Series A Warrants and 28,103 shares of common stock issuable upon exercise of Series B Warrants held by VHCP Co-Investment Holdings III, LLC.

     

    (3)This percentage is calculated based upon (i) 15,055,040 shares of common stock outstanding as of November 1, 2021, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 5, 2021, plus (ii) 984,746 shares of common stock issuable upon exercise of warrants held by the Reporting Persons.

     

     

     

     

    CUSIP No. 82640U107
     
      1. Name of Reporting Persons
    Venrock Healthcare Capital Partners III, L.P.
     
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) x(1)
        (b) o
     
      3. SEC Use Only
     
      4. Citizenship or Place of Organization
    Delaware
         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With:
    5. Sole Voting Power
    0
     
    6. Shared Voting Power
    984,746(2)
     
    7. Sole Dispositive Power
    0
     
    8. Shared Dispositive Power
    984,746(2)
     
      9. Aggregate Amount Beneficially Owned by Each Reporting Person
    984,746(2)
     
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) o
     
      11. Percent of Class Represented by Amount in Row (9)
    6.1%(3)
     
      12. Type of Reporting Person (See Instructions)
    PN
               

     

     

    (1)Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, VHCP Management II, LLC, VHCP Management III, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    (2)Consists of (i) 130,138 shares of common stock issuable upon exercise of Series A Warrants and 130,138 shares of common stock issuable upon exercise of Series B Warrants held by Venrock Healthcare Capital Partners II, L.P.; (ii) 52,721 shares of common stock issuable upon exercise of Series A Warrants and 52,721 shares of common stock issuable upon exercise of Series B Warrants held by VHCP Co-Investment Holdings II, LLC; (iii) 281,411 shares of common stock issuable upon exercise of Series A Warrants and 281,411 shares of common stock issuable upon exercise of Series B Warrants held by Venrock Healthcare Capital Partners III, L.P.; and (iv) 28,103 shares of common stock issuable upon exercise of Series A Warrants and 28,103 shares of common stock issuable upon exercise of Series B Warrants held by VHCP Co-Investment Holdings III, LLC.

     

    (3)This percentage is calculated based upon (i) 15,055,040 shares of common stock outstanding as of November 1, 2021, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 5, 2021, plus (ii) 984,746 shares of common stock issuable upon exercise of warrants held by the Reporting Persons.

     

     

     

     

    CUSIP No. 82640U107
     
      1. Name of Reporting Persons
    VHCP Co-Investment Holdings III, LLC
     
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) x(1)
        (b) o
     
      3. SEC Use Only
     
      4. Citizenship or Place of Organization
    Delaware
         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With:
    5. Sole Voting Power
    0
     
    6. Shared Voting Power
    984,746(2)
     
    7. Sole Dispositive Power
    0
     
    8. Shared Dispositive Power
    984,746(2)
     
      9. Aggregate Amount Beneficially Owned by Each Reporting Person
    984,746(2)
     
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) o
     
      11. Percent of Class Represented by Amount in Row (9)
    6.1%(3)
     
      12. Type of Reporting Person (See Instructions)
    OO
               

     

     

    (1)Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, VHCP Management II, LLC, VHCP Management III, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    (2)Consists of (i) 130,138 shares of common stock issuable upon exercise of Series A Warrants and 130,138 shares of common stock issuable upon exercise of Series B Warrants held by Venrock Healthcare Capital Partners II, L.P.; (ii) 52,721 shares of common stock issuable upon exercise of Series A Warrants and 52,721 shares of common stock issuable upon exercise of Series B Warrants held by VHCP Co-Investment Holdings II, LLC; (iii) 281,411 shares of common stock issuable upon exercise of Series A Warrants and 281,411 shares of common stock issuable upon exercise of Series B Warrants held by Venrock Healthcare Capital Partners III, L.P.; and (iv) 28,103 shares of common stock issuable upon exercise of Series A Warrants and 28,103 shares of common stock issuable upon exercise of Series B Warrants held by VHCP Co-Investment Holdings III, LLC.

     

    (3)This percentage is calculated based upon (i) 15,055,040 shares of common stock outstanding as of November 1, 2021, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 5, 2021, plus (ii) 984,746 shares of common stock issuable upon exercise of warrants held by the Reporting Persons.

     

     

     

     

    CUSIP No. 82640U107
     
      1. Name of Reporting Persons
    VHCP Management II, LLC
     
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) x(1)
        (b) o
     
      3. SEC Use Only
     
      4. Citizenship or Place of Organization
    Delaware
         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With:
    5. Sole Voting Power
    0
     
    6. Shared Voting Power
    984,746(2)
     
    7. Sole Dispositive Power
    0
     
    8. Shared Dispositive Power
    984,746(2)
     
      9. Aggregate Amount Beneficially Owned by Each Reporting Person
    984,746(2)
     
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) o
     
      11. Percent of Class Represented by Amount in Row (9)
    6.1%(3)
     
      12. Type of Reporting Person (See Instructions)
    OO
               

     

     

    (1)Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, VHCP Management II, LLC, VHCP Management III, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    (2)Consists of (i) 130,138 shares of common stock issuable upon exercise of Series A Warrants and 130,138 shares of common stock issuable upon exercise of Series B Warrants held by Venrock Healthcare Capital Partners II, L.P.; (ii) 52,721 shares of common stock issuable upon exercise of Series A Warrants and 52,721 shares of common stock issuable upon exercise of Series B Warrants held by VHCP Co-Investment Holdings II, LLC; (iii) 281,411 shares of common stock issuable upon exercise of Series A Warrants and 281,411 shares of common stock issuable upon exercise of Series B Warrants held by Venrock Healthcare Capital Partners III, L.P.; and (iv) 28,103 shares of common stock issuable upon exercise of Series A Warrants and 28,103 shares of common stock issuable upon exercise of Series B Warrants held by VHCP Co-Investment Holdings III, LLC.

     

    (3)This percentage is calculated based upon (i) 15,055,040 shares of common stock outstanding as of November 1, 2021, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 5, 2021, plus (ii) 984,746 shares of common stock issuable upon exercise of warrants held by the Reporting Persons.

     

     

     

     

    CUSIP No. 82640U107
     
      1. Name of Reporting Persons
    VHCP Management III, LLC
     
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) x(1)
        (b) o
     
      3. SEC Use Only
     
      4. Citizenship or Place of Organization
    Delaware
         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With:
    5. Sole Voting Power
    0
     
    6. Shared Voting Power
    984,746(2)
     
    7. Sole Dispositive Power
    0
     
    8. Shared Dispositive Power
    984,746(2)
     
      9. Aggregate Amount Beneficially Owned by Each Reporting Person
    984,746(2)
     
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) o
     
      11. Percent of Class Represented by Amount in Row (9)
    6.1%(3)
     
      12. Type of Reporting Person (See Instructions)
    OO
               

     

     

    (1)Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, VHCP Management II, LLC, VHCP Management III, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    (2)Consists of (i) 130,138 shares of common stock issuable upon exercise of Series A Warrants and 130,138 shares of common stock issuable upon exercise of Series B Warrants held by Venrock Healthcare Capital Partners II, L.P.; (ii) 52,721 shares of common stock issuable upon exercise of Series A Warrants and 52,721 shares of common stock issuable upon exercise of Series B Warrants held by VHCP Co-Investment Holdings II, LLC; (iii) 281,411 shares of common stock issuable upon exercise of Series A Warrants and 281,411 shares of common stock issuable upon exercise of Series B Warrants held by Venrock Healthcare Capital Partners III, L.P.; and (iv) 28,103 shares of common stock issuable upon exercise of Series A Warrants and 28,103 shares of common stock issuable upon exercise of Series B Warrants held by VHCP Co-Investment Holdings III, LLC.

     

    (3)This percentage is calculated based upon (i) 15,055,040 shares of common stock outstanding as of November 1, 2021, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 5, 2021, plus (ii) 984,746 shares of common stock issuable upon exercise of warrants held by the Reporting Persons.

     

     

     

     

    CUSIP No. 82640U107
     
      1. Name of Reporting Persons
    Shah, Nimish
     
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) x(1)
        (b) o
     
      3. SEC Use Only
     
      4. Citizenship or Place of Organization
    United States
         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With:
    5. Sole Voting Power
    0
     
    6. Shared Voting Power
    984,746(2)
     
    7. Sole Dispositive Power
    0
     
    8. Shared Dispositive Power
    984,746(2)
     
      9. Aggregate Amount Beneficially Owned by Each Reporting Person
    984,746(2)
     
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) o
     
      11. Percent of Class Represented by Amount in Row (9)
    6.1%(3)
     
      12. Type of Reporting Person (See Instructions)
    IN
               

     

     

    (1)Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, VHCP Management II, LLC, VHCP Management III, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    (2)Consists of (i) 130,138 shares of common stock issuable upon exercise of Series A Warrants and 130,138 shares of common stock issuable upon exercise of Series B Warrants held by Venrock Healthcare Capital Partners II, L.P.; (ii) 52,721 shares of common stock issuable upon exercise of Series A Warrants and 52,721 shares of common stock issuable upon exercise of Series B Warrants held by VHCP Co-Investment Holdings II, LLC; (iii) 281,411 shares of common stock issuable upon exercise of Series A Warrants and 281,411 shares of common stock issuable upon exercise of Series B Warrants held by Venrock Healthcare Capital Partners III, L.P.; and (iv) 28,103 shares of common stock issuable upon exercise of Series A Warrants and 28,103 shares of common stock issuable upon exercise of Series B Warrants held by VHCP Co-Investment Holdings III, LLC.

     

    (3)This percentage is calculated based upon (i) 15,055,040 shares of common stock outstanding as of November 1, 2021, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 5, 2021, plus (ii) 984,746 shares of common stock issuable upon exercise of warrants held by the Reporting Persons.

     

     

     

     

    CUSIP No. 82640U107
     
      1. Name of Reporting Persons
    Koh, Bong
     
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) x(1)
        (b) o
     
      3. SEC Use Only
     
      4. Citizenship or Place of Organization
    United States
         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With:
    5. Sole Voting Power
    0
     
    6. Shared Voting Power
    984,746(2)
     
    7. Sole Dispositive Power
    0
     
    8. Shared Dispositive Power
    984,746(2)
     
      9. Aggregate Amount Beneficially Owned by Each Reporting Person
    984,746(2)
     
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) o
     
      11. Percent of Class Represented by Amount in Row (9)
    6.1%(3)
     
      12. Type of Reporting Person (See Instructions)
    IN
               

     

     

    (1)Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, VHCP Management II, LLC, VHCP Management III, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    (2)Consists of (i) 130,138 shares of common stock issuable upon exercise of Series A Warrants and 130,138 shares of common stock issuable upon exercise of Series B Warrants held by Venrock Healthcare Capital Partners II, L.P.; (ii) 52,721 shares of common stock issuable upon exercise of Series A Warrants and 52,721 shares of common stock issuable upon exercise of Series B Warrants held by VHCP Co-Investment Holdings II, LLC; (iii) 281,411 shares of common stock issuable upon exercise of Series A Warrants and 281,411 shares of common stock issuable upon exercise of Series B Warrants held by Venrock Healthcare Capital Partners III, L.P.; and (iv) 28,103 shares of common stock issuable upon exercise of Series A Warrants and 28,103 shares of common stock issuable upon exercise of Series B Warrants held by VHCP Co-Investment Holdings III, LLC.

     

    (3)This percentage is calculated based upon (i) 15,055,040 shares of common stock outstanding as of November 1, 2021, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 5, 2021, plus (ii) 984,746 shares of common stock issuable upon exercise of warrants held by the Reporting Persons.

     

     

     

     

    CUSIP No. 82640U107

     

    Introductory Note: This Schedule 13G/A is filed on behalf of Venrock Healthcare Capital Partners II, L.P., a limited partnership organized under the laws of the State of Delaware (“VHCP II LP”), VHCP Co-Investment Holdings II, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Co-Investment II”), Venrock Healthcare Capital Partners III, L.P., a limited partnership organized under the laws of the State of Delaware (“VHCP III LP”), VHCP Co-Investment Holdings III, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Co-Investment III”), VHCP Management II, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Management II”), VHCP Management III, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Management III” and collectively with VHCP II LP, VHCP Co-Investment II, VHCP III LP, VHCP Co-Investment III and VHCP Management II, the “Venrock Entities”), Nimish Shah (“Shah”) and Bong Koh (“Koh”) in respect of Common Stock of Sierra Oncology, Inc.

     

    Item 1.
      (a) Name of Issuer
    Sierra Oncology, Inc.
      (b)

    Address of Issuer’s Principal Executive Offices

    1820 Gateway Drive, Suite 110

    San Mateo, CA 94404

    Item 2.
      (a)

    Name of Person Filing
    Venrock Healthcare Capital Partners II, L.P.

    VHCP Co-Investment Holdings II, LLC

    Venrock Healthcare Capital Partners III, L.P.

    VHCP Co-Investment Holdings III, LLC

    VHCP Management II, LLC

    VHCP Management III, LLC

    Nimish Shah

    Bong Koh

      (b) Address of Principal Business Office or, if none, Residence
        New York Office: Palo Alto Office:  
        7 Bryant Park 3340 Hillview Avenue  
        23rd Floor Palo Alto, CA 94304  
        New York, NY 10018    
      (c)

    Citizenship

    All of the Venrock Entities were organized in Delaware. The individuals are both United States citizens.

      (d)

    Title of Class of Securities

    Common Stock, par value $0.001 per share

      (e)

    CUSIP Number

    82640U107

     

     

     

     

    CUSIP No. 82640U107

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:
      Not applicable
       
    Item 4. Ownership
      (a) Amount Beneficially Owned as of December 31, 2021:
         
          Venrock Healthcare Capital Partners II, L.P.   984,746 (1)  
          VHCP Co-Investment Holdings II, LLC   984,746 (1)  
          Venrock Healthcare Capital Partners III, L.P.   984,746 (1)  
          VHCP Co-Investment Holdings III, LLC   984,746 (1)  
          VHCP Management II, LLC   984,746 (1)  
          VHCP Management III, LLC   984,746 (1)  
          Nimish Shah   984,746 (1)  
          Bong Koh   984,746 (1)  
                   
      (b) Percent of Class as of December 31, 2021:
         
          Venrock Healthcare Capital Partners II, L.P.   6.1 %  
          VHCP Co-Investment Holdings II, LLC   6.1 %  
          Venrock Healthcare Capital Partners III, L.P.   6.1 %  
          VHCP Co-Investment Holdings III, LLC   6.1 %  
          VHCP Management II, LLC   6.1 %  
          VHCP Management III, LLC   6.1 %  
          Nimish Shah   6.1 %  
          Bong Koh   6.1 %  
                   
      (c) Number of shares as to which the person has, as of December 31, 2021:
        (i) Sole power to vote or to direct the vote
           
          Venrock Healthcare Capital Partners II, L.P.   0    
          VHCP Co-Investment Holdings II, LLC   0    
          Venrock Healthcare Capital Partners III, L.P.   0    
          VHCP Co-Investment Holdings III, LLC   0    
          VHCP Management II, LLC   0    
          VHCP Management III, LLC   0    
          Nimish Shah   0    
          Bong Koh   0    
                   
                       

     

     

     

    CUSIP No. 82640U107

        (ii) Shared power to vote or to direct the vote
           
          Venrock Healthcare Capital Partners II, L.P.   984,746 (1)  
          VHCP Co-Investment Holdings II, LLC   984,746 (1)  
          Venrock Healthcare Capital Partners III, L.P.   984,746 (1)  
          VHCP Co-Investment Holdings III, LLC   984,746 (1)  
          VHCP Management II, LLC   984,746 (1)  
          VHCP Management III, LLC   984,746 (1)  
          Nimish Shah   984,746 (1)  
          Bong Koh   984,746 (1)  
                   
        (iii) Sole power to dispose or to direct the disposition of
           
          Venrock Healthcare Capital Partners II, L.P.   0    
          VHCP Co-Investment Holdings II, LLC   0    
          Venrock Healthcare Capital Partners III, L.P.   0    
          VHCP Co-Investment Holdings III, LLC   0    
          VHCP Management II, LLC   0    
          VHCP Management III, LLC   0    
          Nimish Shah   0    
          Bong Koh   0    
                   
        (iv) Shared power to dispose or to direct the disposition of
           
          Venrock Healthcare Capital Partners II, L.P.   984,746 (1)  
          VHCP Co-Investment Holdings II, LLC   984,746 (1)  
          Venrock Healthcare Capital Partners III, L.P.   984,746 (1)  
          VHCP Co-Investment Holdings III, LLC   984,746 (1)  
          VHCP Management II, LLC   984,746 (1)  
          VHCP Management III, LLC   984,746 (1)  
          Nimish Shah   984,746 (1)  
          Bong Koh   984,746 (1)  
                   
                       

     

    (1)Consists of (i) 130,138 shares of common stock issuable upon exercise of Series A Warrants and 130,138 shares of common stock issuable upon exercise of Series B Warrants held by Venrock Healthcare Capital Partners II, L.P.; (ii) 52,721 shares of common stock issuable upon exercise of Series A Warrants and 52,721 shares of common stock issuable upon exercise of Series B Warrants held by VHCP Co-Investment Holdings II, LLC; (iii) 281,411 shares of common stock issuable upon exercise of Series A Warrants and 281,411 shares of common stock issuable upon exercise of Series B Warrants held by Venrock Healthcare Capital Partners III, L.P.; and (iv) 28,103 shares of common stock issuable upon exercise of Series A Warrants and 28,103 shares of common stock issuable upon exercise of Series B Warrants held by VHCP Co-Investment Holdings III, LLC. VHCP Management II, LLC is the general partner of Venrock Healthcare Capital Partners II, L.P. and the manager of VHCP Co-Investment Holdings II, LLC. VHCP Management III, LLC is the general partner of Venrock Healthcare Capital Partners III, L.P. and the manager of VHCP Co-Investment Holdings III, LLC. Messrs. Shah and Koh are the voting members of VHCP Management II, LLC and VHCP Management III, LLC.

     

    Item 5. Ownership of Five Percent or Less of a Class
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following o.
     
    Item 6. Ownership of More than Five Percent on Behalf of Another Person
    Not Applicable

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.
    Not Applicable

     

     

     

     

    Item 8. Identification and Classification of Members of the Group
    Not Applicable
     
    Item 9. Notice of Dissolution of a Group
    Not Applicable

     

    Item 10. Certification
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 14, 2022

     

    Venrock Healthcare Capital Partners II, L.P.   Venrock Healthcare Capital Partners III, L.P.
             
    By: VHCP Management II, LLC   By: VHCP Management III, LLC
    Its: General Partner   Its: General Partner
             
    By: /s/ David L. Stepp   By: /s/ David L. Stepp
      Name:   David L. Stepp     Name:   David L. Stepp
      Its: Authorized Signatory     Its: Authorized Signatory
               
    VHCP Co-Investment Holdings II, LLC   VHCP Co-Investment Holdings III, LLC
             
    By: VHCP Management II, LLC   By: VHCP Management III, LLC
    Its: Manager   Its: Manager
             
    By: /s/ David L. Stepp   By: /s/ David L. Stepp
      Name: David L. Stepp     Name: David L. Stepp
      Its: Authorized Signatory     Its: Authorized Signatory
               
    VHCP Management II, LLC   VHCP Management III, LLC
             
    By: /s/ David L. Stepp   By: /s/ David L. Stepp
      Name: David L. Stepp     Name: David L. Stepp
      Its: Authorized Signatory     Its: Authorized Signatory
               
    Nimish Shah   Bong Koh
             
    By: /s/ David L. Stepp   By: /s/ David L. Stepp
      David L. Stepp, as attorney-in-fact     David L. Stepp, as attorney-in-fact

     

     

     

     

    CUSIP No. 82640U107

     

    EXHIBITS

     

    A: Joint Filing Agreement (incorporated by reference to Exhibit A to Schedule 13G filed November 25, 2019)

     

    B: Power of Attorney for Nimish Shah (incorporated by reference to Exhibit B to Schedule 13G filed November 25, 2019)

     

    C: Power of Attorney for Bong Koh (incorporated by reference to Exhibit C to Schedule 13G filed November 25, 2019)

     

     

     

    Get the next $SRRA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SRRA

    DatePrice TargetRatingAnalyst
    1/31/2022$35.00 → $51.00Buy
    HC Wainwright & Co.
    11/30/2021$33.00 → $39.00Overweight
    Cantor Fitzgerald
    11/5/2021$29.00 → $35.00Buy
    HC Wainwright & Co.
    9/27/2021$33.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $SRRA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Codexis Announces CEO Transition Effective August 9, 2022

      Dr. Stephen Dilly, Board member and biotechnology veteran, named the next President and CEOJohn Nicols to retire after ten years leading the transformation and growth of Codexis REDWOOD CITY, Calif., July 18, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that its Board of Directors appointed Dr. Stephen Dilly, former CEO of Sierra Oncology, Inc. and current Codexis Board member, as the company's President and CEO, effective August 9, 2022. John Nicols will retire as President and CEO for family reasons after leading the company's transformation and subsequent growth for the last decad

      7/18/22 4:05:00 PM ET
      $CDXS
      $SRRA
      Major Chemicals
      Industrials
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sierra Oncology Announces Submission of New Drug Application for Momelotinib to US Food & Drug Administration

      – Submission seeks approval of momelotinib for the treatment of myelofibrosis – Sierra Oncology, Inc. (NASDAQ:SRRA), a late-stage biopharmaceutical company on a mission to deliver transformative therapies for rare cancers, today announced the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for momelotinib, an ACVR1 / ALK2, JAK1 and JAK2 inhibitor in development for the treatment of myelofibrosis. "Today is truly momentous for everyone at Sierra Oncology and the patients we serve. This team designed a targeted study to address the highest unmet need and delivered incredible results in the midst of a pandemic. We are thrilled to submit this ND

      6/17/22 7:00:00 AM ET
      $SRRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sierra Oncology Announces Oral Presentation of Momelotinib Pivotal Phase 3 Data at European Hematology Association Annual Meeting

      – Oral presentation of MOMENTUM pivotal phase 3 data in myelofibrosis patients who are symptomatic and anemic – – Poster presentation to highlight improved transfusion independence, symptoms and spleen volume of these myelofibrosis patients who also present with thrombocytopenia – Sierra Oncology, Inc. (NASDAQ:SRRA), a late-stage biopharmaceutical company on a mission to deliver transformative therapies for rare cancers, today announced two abstracts have been accepted into the program for the 2022 Annual Meeting of the European Hematology Association (EHA). An abstract presenting the full data from the pivotal phase 3 MOMENTUM study in myelofibrosis patients who are symptomatic and anemi

      5/12/22 10:00:00 AM ET
      $SRRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SRRA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. reiterated coverage on Sierra Oncology with a new price target

      HC Wainwright & Co. reiterated coverage of Sierra Oncology with a rating of Buy and set a new price target of $51.00 from $35.00 previously

      1/31/22 9:32:16 AM ET
      $SRRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald reiterated coverage on Sierra Oncology with a new price target

      Cantor Fitzgerald reiterated coverage of Sierra Oncology with a rating of Overweight and set a new price target of $39.00 from $33.00 previously

      11/30/21 8:05:31 AM ET
      $SRRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Sierra Oncology with a new price target

      HC Wainwright & Co. reiterated coverage of Sierra Oncology with a rating of Buy and set a new price target of $35.00 from $29.00 previously

      11/5/21 12:45:48 PM ET
      $SRRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SRRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Sierra Oncology Inc. (Amendment)

      SC 13D/A - Sierra Oncology, Inc. (0001290149) (Subject)

      7/11/22 4:30:36 PM ET
      $SRRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Sierra Oncology Inc. (Amendment)

      SC 13G/A - Sierra Oncology, Inc. (0001290149) (Subject)

      7/5/22 5:06:15 PM ET
      $SRRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Sierra Oncology Inc. (Amendment)

      SC 13D/A - Sierra Oncology, Inc. (0001290149) (Subject)

      5/6/22 4:33:35 PM ET
      $SRRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SRRA
    Financials

    Live finance-specific insights

    See more
    • Sierra Oncology Announces Momelotinib Achieved Statistically Significant Benefit on Symptoms, Anemia and Splenic Size in the Pivotal MOMENTUM Study for Myelofibrosis

      —New Drug Application submission planned for second quarter of 2022— —Full data set to be presented at an upcoming medical meeting— Sierra Oncology, Inc. (NASDAQ:SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, today announced positive topline data from the pivotal Phase 3 MOMENTUM study—a global, randomized, double-blind clinical trial evaluating momelotinib (MMB) in myelofibrosis patients who are symptomatic and anemic and previously treated with an approved JAK inhibitor. The trial met all of its primary and key secondary endpoints. "These data are extremely exciting and everything we had hoped to see from the trial," said Step

      1/25/22 7:00:00 AM ET
      $SRRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sierra Oncology Signs Exclusive Global In-Licensing Agreement with AstraZeneca for Novel BET Inhibitor to Expand Myelofibrosis Pipeline

       —Combination study to build upon momelotinib's differentiated potential as a cornerstone myelofibrosis therapy-— Sierra Oncology, Inc. (NASDAQ:SRRA), a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, today announced it has acquired an exclusive global license from AstraZeneca (NASDAQ:AZN) for AZD5153, a potent and selective BRD4 BET inhibitor with a novel bivalent binding mode. Sierra plans to initiate a Phase 2 study examining momelotinib in combination with AZD5153 in myelofibrosis patients in the first half of 2022. "This global in-licensing deal is of two-fold importance to Sierra's long-term strategy. First, it brings

      8/5/21 4:05:00 PM ET
      $AZN
      $SRRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SRRA
    SEC Filings

    See more
    • SEC Form 15-12G filed by Sierra Oncology Inc.

      15-12G - Sierra Oncology, Inc. (0001290149) (Filer)

      7/11/22 4:01:52 PM ET
      $SRRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Sierra Oncology Inc.

      EFFECT - Sierra Oncology, Inc. (0001290149) (Filer)

      7/8/22 12:15:18 AM ET
      $SRRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Sierra Oncology Inc.

      EFFECT - Sierra Oncology, Inc. (0001290149) (Filer)

      7/8/22 12:15:23 AM ET
      $SRRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SRRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Vivo Opportunity, Llc returned $183,123,160 worth of shares to the company (3,329,512 units at $55.00)

      4 - Sierra Oncology, Inc. (0001290149) (Issuer)

      7/1/22 4:59:45 PM ET
      $SRRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Orbimed Advisors Llc returned $108,062,350 worth of shares to the company (1,964,770 units at $55.00)

      4 - Sierra Oncology, Inc. (0001290149) (Issuer)

      7/1/22 4:50:05 PM ET
      $SRRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Ashiya Mona returned $108,062,350 worth of shares to the company (1,964,770 units at $55.00)

      4 - Sierra Oncology, Inc. (0001290149) (Issuer)

      7/1/22 4:46:16 PM ET
      $SRRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SRRA
    Leadership Updates

    Live Leadership Updates

    See more
    • Codexis Announces CEO Transition Effective August 9, 2022

      Dr. Stephen Dilly, Board member and biotechnology veteran, named the next President and CEOJohn Nicols to retire after ten years leading the transformation and growth of Codexis REDWOOD CITY, Calif., July 18, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that its Board of Directors appointed Dr. Stephen Dilly, former CEO of Sierra Oncology, Inc. and current Codexis Board member, as the company's President and CEO, effective August 9, 2022. John Nicols will retire as President and CEO for family reasons after leading the company's transformation and subsequent growth for the last decad

      7/18/22 4:05:00 PM ET
      $CDXS
      $SRRA
      Major Chemicals
      Industrials
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RayzeBio Appoints Angie You, Ph.D., to its Board of Directors

      RayzeBio, Inc., a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, appointed Angie You, Ph.D., to its board of directors. Dr. You is a seasoned biotechnology executive and was recently the chief executive officer of Amunix Pharmaceuticals, Inc., where she orchestrated the sale of the Company to Sanofi for over $1.2 billion. She also serves on the board of ORIC Pharmaceuticals, Inc. "RayzeBio is at the forefront of advancing the targeted radiopharmaceuticals modality to development treatment solutions for unmet medical need in solid tumor indications. I have known Ken for over 20 years and am excited to partner with him, the Rayze

      4/25/22 8:00:00 AM ET
      $SRRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ORIC Pharmaceuticals Appoints Angie You, Ph.D., to its Board of Directors

      SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 10, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the appointment of Angie You, Ph.D., to its board of directors. Dr. You currently serves as chief executive officer of Amunix Pharmaceuticals, Inc. "We are delighted to welcome Angie to ORIC's board of directors," said Jacob Chacko, M.D., president and chief executive officer. "Angie's broad experience spanning venture capital, a variety of business development transactions, and public company leadership will bring valuable expertise and in

      11/10/21 4:15:00 PM ET
      $ORIC
      $SRRA
      Biotechnology: Pharmaceutical Preparations
      Health Care